| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Division of Reproductive Endocrinology (I.B.-S., S.K., C.E.R., A.H. D.W.P., E.Y.A.), Department of Obstetrics and Gynecology, and Division of Pediatric Research (L.M.R.), Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland 21201
Address all correspondence and requests for reprints to: Dr. Eli Y. Adashi or Dr. Donna W. Payne, The University of Utah, Department of Obstetrics and Gynecology, Health Sciences Center, Suite 2B200, 50 North Medical Drive, Salt Lake City, Utah 84132. E-mail: eadashi{at}hsc.utah.edu
| Abstract |
|---|
|
|
|---|
and insulin
were inactive; (3) contingent upon cell-cell cooperation (4) and
reliant on de novo protein synthesis. Comparison of the
molar ratios of lactate accumulation to glucose consumption in
IL-1ß-replete vs. IL-1ß-deplete cultures suggests
that IL-ß promotes the conversion of all available glucose to lactate
but that other substrates for lactate production may also exist.
However, no lactate was generated by cells grown under glucose-free
conditions. Taken together, our data suggest that IL-1ß may act as a
metabolic hormone in the ovary. Subject to the limitations of the
in vitro paradigm, our data also suggest that IL-1ß
may mediate the gonadotropin-associated midcycle shift in ovarian
carbohydrate metabolism. By converting the somatic ovarian cells into a
glucose-consuming glycolytic machinery, IL-1ß may establish
glycolysis as the main energy source of the relatively hypoxic
preovulatory follicle and the resultant cumulus-oocyte complex. The
consequent oxygen sparing may conserve the limited supply of oxygen
needed for vital biosynthetic processes such as steroidogenesis. This
adaptational response may also provide the glycolytically incompetent
oocyte with the obligatory tricarboxylic cycle precursors it depends on
to meet the increased energy demands imposed upon it by the resumption
of meiosis. | Introduction |
|---|
|
|
|---|
Yet another corollary of ovulation is the so called metabolic shift, a phenomenon first described more than 30 yr ago by Armstrong and Greep (14). This effect is characterized by the enhancement of glucose uptake as well as by the diversion of ovarian carbohydrate metabolism away from oxidative phosphorylation towards glycolysis (14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24). Although the precise teleologic rationale for the metabolic shift remains unknown, it is possible that it constitutes an adaptational response. Such an adaptational response may be designed to combat the anticipated relative hypoxia experienced by the follicle- or cumulus-enclosed oocyte (24, 25). Moreover, the resultant high throughput of monocarboxylate substrates may be designed to meet the increased energy needs of the meiotically active oocyte that cannot process glucose by itself and therefore relies on alternative energy substrates such as pyruvate and lactate (26, 27, 28, 29, 30).
Because intraovarian IL-1ß appears to be gonadotropin dependent (6) and IL-1ß has been shown to produce an aerobic glycolytic state in several extraovarian cell types (31, 32, 33), we hypothesized that IL-1ß may mediate the gonadotropin-induced midcycle conversion of ovarian metabolism towards glycolysis. To test this possibility, we examined the effect of treatment with IL-1ß on glucose consumption and uptake, and on lactate and pyruvate formation using aerobically cultured whole ovarian dispersates from immature rats. Our results indicate that IL-1ß, of either exogenous or endogenous origin, is capable of inducing glycolysis in aerobically cultured ovarian cells, an effect accompanied by up-regulation of glucose uptake. These findings support the proposition that ovarian IL-1ß-like activity mediates the periovulatory, gonadotropin-induced shift in ovarian glucose metabolism.
| Materials and Methods |
|---|
|
|
|---|
Reagents and hormones
Regular and glucose-free McCoys 5a media (modified, without
serum), penicillin-streptomycin solution, L-glutamine,
trypan blue stain (0.4%), BSA, and HEPES buffer were from Life
Technologies Life Sciences (Grand Island, NY). Collagenase (Clostridium
Histolyticum; CLS type I; 183 U/mg) was from Worthington Biochemical
Corp. (Freehold, NJ). DNase (bovine pancreas; 2100 U/mg),
aminoguanidine hemisulfate salt, and sodium nitroprusside were obtained
from Sigma Chemical Co. (St. Louis, MO).
[3H]L-glucose (20 Ci/mmol),
[1,2-3H]2-deoxy-D-glucose (30.8 Ci/mmol) and
[3H]30-methyl-D-glucose (6090 Ci/mmol)
were obtained from DuPont New England Nuclear Research Products
(Boston, MA).
Recombinant human IL-1ß (2 x 107 U/mg) was
generously provided by Drs. Errol B. De Souza and C. E. Newton of
DuPont-Merck Pharmaceutical Co. (Wilmington, DE). Recombinantly
expressed, naturally occurring human IL-1 receptor antagonist (IL-1RA)
was generously provided by Dr. Jerome F. Strauss III (Philadelphia,
PA). Highly purified human CG (hCG; CR-127, 14, 900 U/mg) and ovine FSH
(oFSH: NIH-FSH-S18, FSH potency equal to 65.6 NIH-FSH-S1 U/mg) were
gifts of the National Hormone and Pituitary Program (Rockville, MD),
through the NIADDK, NICHHD, and USDA. Bovine insulin was obtained from
Sigma Chemical Co. (St. Louis, MO). Recombinant human tumor necrosis
factor-
(TNF
; 5 x 107 U/ng) was generously
provided by Dr. Jennie Mather (Genentech, Inc., San Francisco, CA).
Tissue culture
Whole ovarian dispersates were prepared as previously described
(34). Purified granulosa cells were extracted by repeated follicular
puncture as previously described (35). Highly purified
theca-interstitial cell preparations from immature hypophysectomized
rats were isolated as previously described (36). Cells were cultured in
35 x 10-mm tissue culture dishes (Falcon Plastics, Oxnard, CA)
containing 1 ml of McCoys 5a medium (modified, without serum). Media
were supplemented with L-glutamine (2 mM),
penicillin (100 U/ml), and streptomycin (100 µg/ml). Cell cultures
were maintained for up to 96 h at 37 C under a water-saturated
atmosphere of 5% CO2 and 95% air. At the end of each
experiment, collected conditioned media were stored at -20 C until
assayed for their glucose or lactate content as described below.
Pyruvate was assayed in freshly conditioned media.
Lactate assay
Lactate concentrations in conditioned media were determined by a
modification of a previously described method (37) in which the NADH
product is monitored at 340 nm after the NAD-linked conversion of
lactate to pyruvate by lactate dehydrogenase with hydrazine trapping of
pyruvate to ensure that the reaction goes to completion. The assay was
adapted as follows to a microtiter plate system using premixed reagents
from a commercially available kit (Sigma no. 826-A, Sigma Chemical Co.,
St. Louis, MO). Conditioned media (20 µl of 20-fold diluted) or
varying volumes (20100 µl) of L-lactic acid standard (50 µg/ml)
were diluted in the microtiter plate wells to a volume of 100 µl
after which were added NAD/glycine buffer solution, pH 9.2 (75 µl),
and lactate dehydrogenase solution (25 µl). After a 30-min incubation
period at ambient temperature, absorbance (340 nm) was read in a UVmax
plate reader (Molecular Devices, Menlo Park, CA). The standard curve
was linear in the range used (125 µg/ml), and media blanks were
negligible. Lactate concentrations were calculated from the standard
curve using a software package (
Soft, BioMetallics, Inc., Princeton,
NJ) designed for the plate reader. The within-assay coefficients of
variation were 14.5 and 6.9% and the between-assay coefficients of
variation were 11.7 and 6.7% for the low and high standards,
respectively.
Glucose assay
Glucose concentrations in conditioned media were determined by
the modification of a previously described enzymatic method (38)
wherein the glucose oxidase and peroxidase reactions are coupled with
the chromogenic oxygen acceptor o-dianisidine. The assay was adapted as
follows to a microtiter plate system using premixed reagents from a
commercially available kit (Sigma no. 510-A, Sigma). Unconditioned or
conditioned media (10 µl of 20-fold diluted) or varying volumes
(1.530 µl) of standard glucose solution (50 µg/ml) were diluted
in the microtiter plate wells to a volume of 30 µl to which were
added the color reagent/enzyme solution (200 µl), prepared as
described by the manufacturer. After a 45-min incubation period at
ambient temperature, absorbance of oxidized o-dianisidine (450 nm) was
read in the UVmax plate reader. The standard curve was linear in the
range used (2.550 µg/ml). Glucose concentrations were calculated
from the standard curve. The within-assay coefficients of variation
were 2.7 and 1.2% and the between-assay coefficients of variation were
3.2 and 1.5% for the low and high standards, respectively. The values
for glucose consumption reported herein were calculated by subtracting
the value determined in conditioned media (a value containing assay
variability, see below) from the glucose value in unconditioned media.
This latter number is nominally 3 mg glucose/ml media (16.7
mM), but in reality varied slightly due to modest
evaporation during culture. A value of 3.02 ± 0.13 mg glucose/ml
(range 2.93.3 mg/ml) was actually measured in McCoys media after
96 h in cell-free cultures (n = 12).
In preliminary studies, glucose was also measured by a previously described coupled reaction (39) in which glucose is first phosphorylated and the glucose-6-phosphate formed is oxidized in the presence of NAD. When we compared glucose measurement by this technique to that of the glucose oxidase method described above, both methods gave comparable results. The correlation coefficient (r2) for the two methods, using data from five different experiments (n = 36 determinations for each method), was 0.66 (P = 0.0001). The slope (glucose oxidase method/NAD method) was 1.03 (P = 0.0001), indicating that the two methods gave essentially the same value for glucose concentration.
Pyruvate assay
Pyruvate concentrations in conditioned media were assayed by the
same enzymatic reaction used to measure lactate as described above, but
in the reverse direction (37). The loss of NADH is monitored at 340 nm
after the NADH-linked conversion of pyruvate to lactate by lactate
dehydrogenase. The assay was adapted as follows to a microtiter plate
system using premixed reagents from a commercially available kit (Sigma
no. 726-UV). Unconditioned or conditioned media (100 µl), or varying
volumes (560 µl) of pyruvic acid standard (0.45 mM)
were diluted in the microtiter plate wells to a volume of 100 µl
after which an additional 100 µl of NADH (0.67 mM) in
Tris buffer (1.5 M) was added. Initial absorbance (340 nm)
was then read in a UVmax plate reader after which 25 µl lactate
dehydrogenase solution (160 U/ml) was added to initiate the reaction.
After a 15-min incubation period at ambient temperature, final
absorbance (340 nm) was read and the change in absorbance was
calculated for each sample. Pyruvate concentrations were calculated
from the standard curve.
Glucose uptake assay
The rate of glucose transport was measured using the glucose
analogs [1,2-3H]2-deoxy-D-glucose or
[3H]30-methyl glucose. Plated, pretreated cells were
washed (x3) with HEPES buffer, pH 7.4, and the final wash immediately
replaced with 1 ml of the reaction mix containing 1 mM of
3H-labeled and unlabeled substrate. The dishes were then
placed on a rotary shaker and incubated at room temperature. At the end
of the reaction time (up to 15 min), the reaction mixture was aspirated
off and the cells quickly washed (x4) with stopping solution [NaCl
(0.9%); HgCl2 (10-5 M); phloretin
(10-4 M)]. The cells were allowed to dry
overnight, then dissolved in NaOH (0.1 M). A portion of
each sample was transferred to a plastic counting vial, scintillation
fluor added, and the radioactivity determined. Nonspecific uptake
(accounting for nontransporter-mediated transmembranal glucose passage)
was measured for each time point by incubating the cells with a mixture
of 3H-labeled and unlabeled L-glucose (final
concentration = 1 mM). Net specific uptake was
calculated by subtracting the nonspecific from the total uptake, the
results being expressed as pmol/min·mg protein.
Data analysis
Data are presented as the mean ± SE of
replicate experiments (n noted on figures), each performed in
duplicate. Statistical significance is denoted in the figures and was
determined by ANOVA analysis for comparison of multiple groups
(Fishers protected least significant difference) or by t
test for comparison of two groups, using Statview 512+ for MacIntosh
(Brain Power, Inc., Calabasas, CA).
| Results |
|---|
|
|
|---|
|
The pH of media (normally pH 7.4) conditioned by IL-1ß-treated cells was lowered by approximately 0.5 U as evidenced by the distinct yellowish color of the phenol red indicator dye. Media acidity apparently reflected the accumulation of lactic acid since IL-1ß-treated cells that did not accumulate lactate (e.g. those cultured in glucose-free media, see below) did not demonstrate a pH change. The change in pH did not account for the metabolic alterations under study in that qualitatively comparable findings were documented in appropriately buffered (pH stable) media (not shown).
The specificity of the IL-1ß metabolic effect was assessed using two
other established ovarian agonists (34, 35). In contrast to IL-1ß,
maximally effective doses of TNF
(a cytokine possessing an
overlapping range of action) or insulin (an established metabolic
hormone) were unable to stimulate glucose consumption or lactate
accumulation (Fig. 2
). The inability of insulin to
promote ovarian glucose consumption is in keeping with preliminary data
(not shown) suggesting that the ovary does not express
insulin-regulatable glucose transporters.
|
|
The IL-1ß action on glucose consumption and lactate accumulation was
receptor-mediated because addition of IL-1RA (Fig. 3
; open
triangles), a reagent previously validated at the ovarian level
(42), blocked the IL-1ß effect thereby approximating control levels
(closed triangles) at all glucose concentrations. Treatment
with IL-1RA alone (open squares) was without significant
effect.
Comparison of lactate accumulation and glucose consumption under
IL-1ß-replete and IL-1ß-deplete conditions
To compare the relative contribution of glucose consumption to
lactate accumulation at the extremes of IL-1ß exposure, whole ovarian
dispersates were cultured for varying durations with either IL-1ß
(IL-1ß-replete) or a maximally inhibitory dose of IL-1RA
(IL-1ß-deplete). Exposure of whole ovarian dispersates to maximally
stimulatory levels of IL-1ß markedly increased the molar ratio of
lactate produced to glucose consumed. The resultant ratio (2.5 ±
0.2; range 2.22.9; n = 3) was higher than 2 (the ratio expected
if glucose is completely converted to lactate), suggesting, consistent
with previous reports (16, 43), that substrates other than glucose may
be used for lactate production. Nevertheless, if other sources
(e.g. amino acids) exist, they are only processed in the
presence of glucose because no lactate is produced in the total absence
of glucose (cf. Fig. 3
). All told, these data highlight the remarkable
efficiency of the IL-1ß-stimulated conversion of glucose to lactate.
In contrast, given IL-1ß-deplete conditions, i.e. an
IL-1ß vacuum created by the addition of IL-1RA (42), the ratio of
lactate accumulation to glucose consumption, (0.99 ± 0.4; range
0.51.8; n = 3) suggests a higher rate of oxidative
phosphorylation or the possible diversion of glucose to nonglycolytic
pathways. The large variability noted in this ratio for IL-1RA-treated
cultures probably reflects the fact that the absolute consumption of
glucose and the production of lactate in this state is very low, the
values in question being at the limit of detection. These data also
emphasize the stimulatory effect of both endogenous and exogenous
IL-1ß on ovarian glycolysis.
IL-1ß-stimulated aerobic glycolysis: time and cell density
dependence
To evaluate the time requirements of the IL-1ß effect, whole
ovarian dispersates were cultured for the duration indicated in the
absence or presence of a maximal stimulatory dose of IL-1ß. As shown
(Fig. 4
), treatment with IL-1ß resulted in marked
enhancement (of up to 2.2-fold) of both parameters beginning with the
48-h time point. Whereas treatment with IL-1ß produced a
statistically significant increment in lactate accumulation by 48
h, significant alteration in glucose consumption was only documented by
the 72 h time point. No IL-1ß effect was noted for a series of
time points during the first 48 h (not shown). This initial delay
is suggestive of the induction of an intermediate factor(s) between
IL-1ß stimulation and the final endpoint of glucose consumption and
lactate production. In fact, when cells were cultured in the presence
of cycloheximide (0.1 µg, an inhibitor of protein synthesis),
IL-1ß-stimulated glucose consumption and lactate accumulation was
completely inhibited (n = 3 experiments; not shown). These data
suggest that protein synthesis is required for IL-1ß-driven
glycolysis.
|
Effect of treatment with gonadotropins on glucose consumption and
lactate accumulation: intermediary role of endogenous IL-1ß
Because gonadotropins have previously been implicated in the
induction of the midcycle metabolic shift (14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24), we examined the
impact of treatment with gonadotropins on ovarian glycolysis as well as
on the intermediary paracrine role of endogenous IL-1ß in this
regard. Whole ovarian dispersates were cultured for 96 h in the
absence or presence of maximally stimulating doses of hCG or FSH, with
or without IL-1RA. As shown (Fig. 5
), treatment with
either FSH or hCG produced significant (P < 0.05),
albeit modest (3040%), increments in glucose consumption and lactate
accumulation. Furthermore, the concurrent provision of IL-1RA,
significantly (P < 0.05) reduced the FSH and hCG
effects to below control levels thereby implicating endogenous
IL-1-like activity as an intermediary in this process.
|
|
|
|
| Discussion |
|---|
|
|
|---|
Characterization of the IL-1ß metabolic effect revealed it to be
receptor mediated (Fig. 3
) and dose (Fig. 1
), time (Fig. 4
)- and cell
density (Fig. 4
; inset) dependent but glucose
concentration-independent (Fig. 3
). The IL-1ß action was relatively
specific in that other ovarian effectors, TNF
(35), and insulin (34)
were incapable of producing a similar effect (Fig. 2
). Of particular
note is the lack of effect by insulin on glucose consumption in the
ovary. These data suggest that ovarian glucose transporters do not
include the insulin-coupled variety (glucose transporter 4).
Importantly, the IL-1ß-induced increase in glucose consumption was
associated with an increase in glucose uptake (Fig. 8
). This phenomenon
could be attributable to an increase in the number of glucose
transporter proteins in IL-1ß-treated ovarian cells. Such a
possibility is supported by the observation that IL-1ß up-regulates
the steady-state levels of transcripts and of proteins corresponding to
several glucose transporters in a number of extraovarian cell types
(47, 48).
The ability of IL-1ß to bring about a metabolic shift in ovarian
cells was time dependent but not immediate (Fig. 4
). Neither glucose
consumption nor lactate generation could be detected up to 24 h in
culture even in the presence of IL-1ß. The promotion of glucose
uptake and the induction of the glycolytic state may require an
as-yet-to-be defined set of transcriptional/translational events
without that the cellular reprogramming may not be realized. For
example, the modulation of distinct species of glucose transporter(s),
monocarboxylate transporters, glutamate transporter(s), and/or of
select glycolytic and oxidative enzymes may take place. Studies are
currently underway to examine these possibilities.
Our observation that the IL-1ß-induced metabolic shift in ovarian
glucose utilization is reversed by IL-1RA (Fig. 3
) is an indication
that this effect is receptor-mediated. In addition, treatment with
IL-1RA attenuated the metabolic actions of FSH and hCG (Fig. 5
),
suggesting the existence of endogenously produced, IL-1-like
bioactivity. Given the ability of LH/hCG to increase the steady state
levels of intraovarian IL-1ß transcripts in the preovulatory rat
ovary (6), it is conceivable that the in vivo ability of the
midcycle gonadotropin surge to effect a metabolic shift may be due, in
part, to the preovulatory induction of intraovarian IL-1ß.
Our findings (Fig. 6
) suggest that the full magnitude of the metabolic
shift requires both cellular components of the follicle
(i.e. the granulosa and theca-interstitial cells). These
observations are in keeping with previous reports that the ovarian
action of IL-1ß is contingent on contact-independent cell-cell
cooperation (11, 12, 13).
A metabolic shift of the nature we describe in this study may be the result of multiple regulatory effects on several metabolic pathways. Indeed, significant differences were noted in the molar ratio of lactate produced to glucose consumed when comparing IL-1ß-replete and IL-1ß-deplete circumstances. In the presence of maximally stimulating levels of IL-1ß, 2.5 ± 0.2 lactate molecules were produced per glucose molecule consumed. In an IL-1RA-induced IL-1ß vacuum, this ratio was only 0.9 ± 0.4. These observations suggest that in the presence of IL-1ß, every available glucose molecule is converted to lactate (expected ratio of 2). That the ratio is even higher (2.5 ± 0.2) suggests, consistent with previous reports (16, 43), that lactate-generating sources other than glucose may have been used in IL-1ß-treated cultures. The exact nature and relative contribution of such accessory precursors (e.g. glutamine, alanine, glycogen, or other substrates) is of interest and is currently under active investigation in our laboratory.
Our data further demonstrate an IL-1ß-mediated decrease in media
pyruvate accumulation (Fig. 7
), concordant with the IL-1ß-mediated
increase in lactate accumulation. This decline in pyruvate most likely
reflects a change in the redox state of the cell, resulting from
IL-1ß-stimulated glycolysis. Indeed, the glycolytically induced
depletion of NAD would be expected to drive the conversion of pyruvate
to lactate to generate additional NAD to maintain the glycolytic
process. However, pyruvate depletion could also be related to the
activation and/or utilization of other metabolic pathways. For example,
IL-1ß-treated cells may increase the uptake of pyruvate into the
tricarboxylic acid cycle via pyruvate carboxylase, its conversion to
alanine, or its utilization as a metabolic scavenger of oxygen-free
radicals. In vivo, the requisite utilization of pyruvate by
the glycolytically incompetent oocyte may drive the depletion of
pyruvate from the glycolytically competent somatic cells.
The mechanism by which IL-1ß provokes the transition to glycolysis
remains to be determined. It may be that the IL-1ß-stimulated
increase in glucose uptake (Fig. 8
) triggers the glucose-mediated
enhancement of aerobic glycolysis as described by Crabtree (49).
Whether IL-1ß also exerts direct stimulatory effects on glycolytic
enzymes is a subject for future investigation.
In summary, these observations lend support to the notion that IL-1ß serves as a mediator of the gonadotropin-associated midcycle shift in ovarian carbohydrate metabolism. The rationale for such a shift remains a mystery. It could be argued that the conversion of the somatic ovarian cell into a glycolytic machinery is necessary to meet the energy needs of the maturing but glycolytically inactive (26, 27, 28, 29) oocyte, which depends on extracellular (cumulus cell-derived) sustenance (50, 51, 52, 53, 54) in general and on monocarboxylate glycolytic products in particular (26, 27, 28, 29). Conceivably, the relatively hypoxic oocyte environment (25) may require a sparing of the utilization of oxygen by the tricarboxylic acid cycle thereby conserving oxygen for other vital tasks such as steroidogenesis. Leese et al. (43) have suggested that the early shift toward aerobic glycolysis may prepare embryos for the relatively anoxic environment of implantation. Alternatively, metabolic antioxidants, such as pyruvate (55), may protect the oocyte from oxygen-free radicals, which may be generated during the dynamic periovulatory period. Undoubtedly, other possibilities exist. In any case, these studies, for the first time, implicate IL-1ß as a key player in modulating the energy needs of the cycling ovary, a topic first addressed in 1962 (14).
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Current address: Department of Obstetrics and Gynecology, Haemek
Medical Center, Afula, Israel. ![]()
3 Current address: Department of Obstetrics and Gynecology,
Rambam Medical Center, Haifa, Israel. ![]()
4 Current address: Department of Obstetrics and Gynecology,
Hadassa University Hospital, Mount Scopus, Jerusalem, Israel. ![]()
5 Current address: The University of Utah, Department of Obstetrics
and Gynecology, Health Sciences Center, Suite 2B200, 50 North Medical
Drive, Salt Lake City, Utah 84132. ![]()
Received November 4, 1996.
| References |
|---|
|
|
|---|
inhibits the differentiation of
non-transformed ovarian granulosa cells: A cytodifferentiative
non-cytotoxic property. J Biol Chem 264:1159111597
. FEBS
Lett 2:421424
This article has been cited by other articles:
![]() |
S. F. Abcouwer, S. Shanmugam, P. F. Gomez, S. Shushanov, A. J. Barber, K. F. Lanoue, P. G. Quinn, M. Kester, and T. W. Gardner Effect of IL-1{beta} on Survival and Energy Metabolism of R28 and RGC-5 Retinal Neurons Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5581 - 5592. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Taneja, P. E. Coy, I. Lee, J. M. Bryson, and R. B. Robey Proinflammatory interleukin-1 cytokines increase mesangial cell hexokinase activity and hexokinase II isoform abundance Am J Physiol Cell Physiol, August 1, 2004; 287(2): C548 - C557. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |